What is the price-to-earnings ratio of PharmAbcine?
The price-earnings ratio of PharmAbcine is currently 1.08.
PharmAbcine P/S 2024
PharmAbcine P/S
1.08
Ticker
208340.KQ
ISIN
KR7208340000
As of Oct 7, 2024, PharmAbcine's P/S ratio stood at 1.08, a -99.85% change from the 697.29 P/S ratio recorded in the previous year.
The PharmAbcine P/S history
PharmAbcine Aktienanalyse
What does PharmAbcine do?
PharmAbcine ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding PharmAbcine's P/S Ratio
PharmAbcine's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing PharmAbcine's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating PharmAbcine's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in PharmAbcine’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about PharmAbcine stock
How has the price-earnings ratio of PharmAbcine changed compared to last year?
The price-to-earnings ratio of PharmAbcine has increased by -99.85% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of PharmAbcine high compared to other companies?
Yes, the price-to-earnings ratio of PharmAbcine is high compared to other companies.
How does an increase in the price-earnings ratio of PharmAbcine affect the company?
An increase in the price-earnings ratio of PharmAbcine would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of PharmAbcine affect the company?
A decrease in the price-earnings ratio of PharmAbcine would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of PharmAbcine?
Some factors that influence the price-earnings ratio of PharmAbcine are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does PharmAbcine pay?
Over the past 12 months, PharmAbcine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PharmAbcine is expected to pay a dividend of 0 KRW.
What is the dividend yield of PharmAbcine?
The current dividend yield of PharmAbcine is .
When does PharmAbcine pay dividends?
PharmAbcine pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of PharmAbcine?
PharmAbcine paid dividends every year for the past 0 years.
What is the dividend of PharmAbcine?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is PharmAbcine located?
PharmAbcine is assigned to the 'Health' sector.
Wann musste ich die Aktien von PharmAbcine kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of PharmAbcine from 10/7/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.
When did PharmAbcine pay the last dividend?
The last dividend was paid out on 10/7/2024.
What was the dividend of PharmAbcine in the year 2023?
In the year 2023, PharmAbcine distributed 0 KRW as dividends.
In which currency does PharmAbcine pay out the dividend?
The dividends of PharmAbcine are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von PharmAbcine
Our stock analysis for PharmAbcine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmAbcine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.